ARCT - Is Arcturus Therapeutics a Buy?
Now that the first approved coronavirus vaccines are rolling out worldwide, investors everywhere are scanning the horizon for signs of which biotech stock will be the next to hit it big. You've already heard about how Moderna impressed the world with the speed at which it developed its COVID-19 vaccine. But you may not have heard of Arcturus Therapeutics (NASDAQ: ARCT) , a smaller company that took a similar scientific approach, though without striking gold -- at least, not yet.
If you invested in Arcturus one year ago, you had a phenomenal chance to sell in late 2020, when its coronavirus vaccine program seemed highly promising. Since then, its price has collapsed, which could make this an opportune moment to buy in -- assuming there's a credible chance that a catalyst that could push the stock back up again.
Image source: Getty Images.
For further details see:
Is Arcturus Therapeutics a Buy?